Sinopharm’s China TCM Buyout Bid Lapses Without Regulatory Nods

Bloomberg10-18

(Bloomberg) -- China National Pharmaceutical Group Co.’s latest attempt to take China Traditional Chinese Medicine Holdings Co. private has fallen through as it was unable to secure necessary ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476025559?lang=en_US&edition=fundamental","thumbnail":"https://static.themebuilder.aws.arc.pub/bellmediainc/1717607291216.jpg","is_english":true,"pubTime":"2024-10-18 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476025559","market":"hk","top_or_hot":-1,"title":"Sinopharm’s China TCM Buyout Bid Lapses Without Regulatory Nods","media":"Bloomberg","content":"<div>\n<p>(Bloomberg) -- China National Pharmaceutical Group Co.’s latest attempt to take China Traditional Chinese Medicine Holdings Co. private has fallen through as it was unable to secure necessary ...</p>\n\n<a href=\"https://www.bnnbloomberg.ca/investing/2024/10/18/sinopharms-china-tcm-buyout-bid-lapses-without-regulatory-nods/\">Source Link</a>\n\n</div>\n","source":"bnn_bloomberg_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm’s China TCM Buyout Bid Lapses Without Regulatory Nods</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm’s China TCM Buyout Bid Lapses Without Regulatory Nods\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-18 21:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bnnbloomberg.ca/investing/2024/10/18/sinopharms-china-tcm-buyout-bid-lapses-without-regulatory-nods/><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- China National Pharmaceutical Group Co.’s latest attempt to take China Traditional Chinese Medicine Holdings Co. private has fallen through as it was unable to secure necessary ...</p>\n\n<a href=\"https://www.bnnbloomberg.ca/investing/2024/10/18/sinopharms-china-tcm-buyout-bid-lapses-without-regulatory-nods/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0640798160.USD","symbol_name":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","start_time":0,"source_url":"https://www.bnnbloomberg.ca/investing/2024/10/18/sinopharms-china-tcm-buyout-bid-lapses-without-regulatory-nods/","article_id":"2476025559","we_media_id":null,"thumbnails":["https://static.themebuilder.aws.arc.pub/bellmediainc/1717607291216.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476025559","pubTimestamp":1729256921,"columns":[],"sourceInfo":{"source_id":"bnn_bloomberg_highlight","name":"Bloomberg"},"weMediaInfo":null,"summary":"China National Pharmaceutical Group Co.’s latest attempt to take China Traditional Chinese Medicine Holdings Co. private has fallen through as it was unable to secure necessary regulatory approval from Chinese regulators.","collect":0,"end_time":0,"defaultTopTitle":"bnnbloomberg.ca","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK1197":"保健护理产品经销商","BK1500":"做空集合股","01099":"国药控股","BK1515":"抗疫概念"},"translate_title":"国药控股对中国中药的收购要约在未经监管机构批准的情况下失败","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"(Bloomberg) -- China National Pharmaceutical Group Co.’s latest attempt to take China Traditional Chinese Medicine Holdings Co. private has fallen through as it was unable to secure necessary regulatory approval from Chinese regulators.  The state-backed company, known as Sinopharm, didn’t receive the necessary approvals from Chinese regulators for outbound direct investment — one of the deal’s pre-conditions — by Friday and the proposed privatization deal for China TCM had lapsed, according to a joint statement to the Hong Kong exchange. Under the terms of the proposal, Sinopharm would need ODI approvals from Chinese regulators including the State-owned Assets Supervision and Administration Commission, the National Development and Reform Commission, the Ministry of Commerce and the State Administration of Foreign Exchange. The joint statement did not identify which regulator didn’t approve the deal.In February, Sinopharm offered HK$4.6 per share in cash, or HK$15.6 billion ($2 billion) in total, to take the Hong Kong-listed drugmaker unit private. The lapse of the Sinopharm’s privatization bid for China TCM marks another setback for the company after it abandoned a previous attempt to do so in 2022. Bloomberg News reported in 2022 that state-backed Sinopharm was discussing an offer of about HK$6 a share. Sinopharm may not make another privatization attempt within the next 12 months under the existing takeovers code in Hong Kong. ©2024 Bloomberg L.P.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476025559"}